Amgen R&D EVP James Bradner On Upcoming Readouts And Doing Deals Around New Capabilities

Phase III Data In 2026 In Cancer And Other Diseases

 
• By Mandy Jackson
  
Its recent Dark Blue and DISCO deals will help build out Amgen's R&D capabilities (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from J.P. Morgan

More from Conferences